Low-Dose Tirzepatide: Short-Term Effects on Lipids, Glucose, and Inflammation

What the researchers found

Short-term low-dose tirzepatide improved lipid profiles, glucose homeostasis, and inflammatory markers, showing metabolic benefits begin even at starting doses.

Why it matters

Relevant to peptide therapeutics.

The numbers in context

Specific numerical changes not detailed in abstract; study measured lipids, glucose parameters, and hepatic steatosis index at baseline and follow-up.

How the study worked

In publication.

Who was studied

Adults with obesity without diabetes mellitus

What this study cannot tell us

In publication.

How to read the evidence

Based on design.

When this study was published

Published in 2025.

The bigger picture

Advances peptide evidence.

Questions still open

• Long-term implications?
• Evidence comparison?
• Next steps?

Common questions

Read the original research

Short-term effects of low-dose tirzepatide on lipid profile, glucose homeostasis and hepatic steatosis index in adults with obesity, but without diabetes mellitus: a prospective observational study.

Journal of diabetes and its complications, 39(12), 109181

Citation

Angelopoulos, Nikolaos; Livadas, Sarantis; Androulakis, Ioannis; Petkova, Valentina; Rizoulis, Andreas; Boniakos, Anastasios; Paparodis, Rodis; Tzoulis, Ploutarchos; Mentzelopoulou, Voula; Florakis, Dimos; Fousteris, Evangelos; Korakovouni, Areti; Zianni, Dimitra; Mouslech, Zadalla; Rizzo, Manfredi; Mikhailidis, Dimitri P; Anagnostis, Panagiotis. (2025). Short-term effects of low-dose tirzepatide on lipid profile, glucose homeostasis and hepatic steatosis index in adults with obesity, but without diabetes mellitus: a prospective observational study.. Journal of diabetes and its complications, 39(12), 109181. https://doi.org/10.1016/j.jdiacomp.2025.109181